{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:21:12Z","timestamp":1791181272191,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1136\/ard.2007.076604","type":"journal-article","created":{"date-parts":[[2007,7,21]],"date-time":"2007-07-21T00:34:01Z","timestamp":1184978041000},"page":"353-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":117,"title":["Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"67","author":[{"given":"F","family":"Chopin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Garnero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"le Henanff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Debiais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Daragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Sany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Wendling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Zarnitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.076604_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bone.2004.07.004","article-title":"TNF alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflamation through distinct mechanisms in collagen-induced arthritis","volume":"35","author":"Saidenberg-Kermanac'h","year":"2004","journal-title":"Bone"},{"key":"10.1136\/ard.2007.076604_bib2","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.4049\/jimmunol.163.9.5049","article-title":"IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation","volume":"163","author":"Joosten","year":"1999","journal-title":"J Immunol"},{"issue":"Suppl II","key":"10.1136\/ard.2007.076604_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.61.suppl_2.ii84","article-title":"Bone destruction in arthritis","volume":"61","author":"Gravallese","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.076604_bib4","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/art.1780361105","article-title":"The effect of rheumatoid arthritis and steroid therapy one bone density in post menopausal women","volume":"36","author":"Hall","year":"1993","journal-title":"Athritis Rheum"},{"key":"10.1136\/ard.2007.076604_bib5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1521-6942(03)00041-X","article-title":"Co-morbidity in rheumatoid arthritis","volume":"17","author":"Mikuls","year":"2003","journal-title":"Best Prac Res Clin Rheumatol"},{"key":"10.1136\/ard.2007.076604_bib6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1002\/art.10408","article-title":"Bone loss in patients with rheumatoid arthritis","volume":"46","author":"Haugeberg","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076604_bib7","first-page":"153","article-title":"How useful are bone turnover markers in rheumatois arthritis? Influence of disease activity and corticosteroid therapy","volume":"64","author":"Cortet","year":"1997","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1136\/ard.2007.076604_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF00310403","article-title":"Persistent bone-sparing effect of interleukin-I receptor antagonist: a hypothesis of the role of IL-I in ovariectomy induced bone loss","volume":"55","author":"Kimble","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"10.1136\/ard.2007.076604_bib9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/01.moo.0000127830.72761.00","article-title":"Noninvasive techniques for assesing skeletal changes in inflammatory arthritis: bone biomarkers","volume":"16","author":"Garnero","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2007.076604_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S8756-3282(00)00235-0","article-title":"Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K","volume":"26","author":"Sassi","year":"2000","journal-title":"Bone"},{"key":"10.1136\/ard.2007.076604_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","article-title":"The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2007.076604_bib12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/rheumatology\/36.6.643","article-title":"Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti tumour necrosis factor alpha therapy","volume":"36","author":"Brennan","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.076604_bib13","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1074\/jbc.272.13.8109","article-title":"Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption","volume":"272","author":"Inui","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.2007.076604_bib14","first-page":"S54","article-title":"Biochemical markers of joint tissue turnover in early rheumatoid arthritis","volume":"21","author":"Garnero","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.076604_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/1529-0131(200201)46:1<21::AID-ART10061>3.0.CO;2-Q","article-title":"Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagene C telopeptide are associated with progression of joint destruction in patients with early rhumatoid arthritis","volume":"46","author":"Garnero","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076604_bib16","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/art.10616","article-title":"Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study","volume":"46","author":"Garnero","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076604_bib17","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/art.20930","article-title":"Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis","volume":"52","author":"Charni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076604_bib18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1139\/h04-040","article-title":"Validity and reliability of the Huet questionnaire to assess maximal oxygen uptake","volume":"29","author":"Trivel","year":"2004","journal-title":"Can J Appl Physiol"},{"key":"10.1136\/ard.2007.076604_bib19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0531-5565(03)00069-X","article-title":"Molecular mechanisms underlying osteoclast formation and activation","volume":"38","author":"Troen","year":"2003","journal-title":"Exp Gerontol"},{"key":"10.1136\/ard.2007.076604_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1359\/JBMR.050905","article-title":"Degradation of the organic phase of bone by osteoclast: a secondary role for lysosomal acidification","volume":"21","author":"Henriksen","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2007.076604_bib21","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","article-title":"Increase in bone mineral density of patients with rheumatoid arthritis treated with anti TNF-alpha antibody: a prospective open-label pilot study","volume":"44","author":"Lange","year":"2005","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.076604_bib22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/ard.2003.017780","article-title":"Bone mineral density in patients with rheumatoid arthritis treated with infliximab","volume":"64","author":"Vis","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.076604_bib23","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis","volume":"65","author":"Vis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.076604_bib24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/ard.2004.028670","article-title":"Body weight, body composition, and bone turnover changes in patients with spondylarthropathy receiving anti-tumour necrosis factor \u03b1 treatment","volume":"64","author":"Briot","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.076604_bib25","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/art.11292","article-title":"Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab","volume":"48","author":"Vis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076604_bib26","first-page":"1038","article-title":"Assay for crosslinked carboxyterminal telopeptide of type I collagen (ICTP) unlike Crosslaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis","volume":"41","author":"Sassi","year":"2003","journal-title":"Clin Chem Lab"},{"key":"10.1136\/ard.2007.076604_bib27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/rheumatology\/41.5.484","article-title":"Anti-tumor necrosis factor-alpha therapy (etanercept) down regulates serum matrix metallopreoteinase (MMP)-3 and MMP-1 in rheumatoid arthritis","volume":"41","author":"Catrina","year":"2002","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.076604_bib28","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/1529-0131(200110)44:10<2263::AID-ART389>3.0.CO;2-1","article-title":"Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinase 1 in rheumatoid arthritis","volume":"44","author":"Cunnane","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.076604_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S8756-3282(01)00677-9","article-title":"Hypercorticism blunts circadian variations of osteocalcin regardless of nutritional status","volume":"30","author":"Vergely","year":"2002","journal-title":"Bone"},{"key":"10.1136\/ard.2007.076604_bib30","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.20222","article-title":"Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis","volume":"50","author":"Landewe","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724218756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724218756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.076604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T05:47:14Z","timestamp":1737352034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724218756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0003496724218756"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.076604","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.076604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}